Skip to main content
. 2021 May 29;22(11):5850. doi: 10.3390/ijms22115850

Table 6.

Ongoing clinical trials for the patients with schwannomatosis.

ID Initiation Date Phase Nation N Disease Treatment Primary Outcome
NCT04163419 4, 2020 2 USA 46 Schwannomatosis Tanezumab Change in pain level
NCT04085159 9, 2019 1/2 China 100 Neurofibromatosis Schwannomatosis Antigen-specific T cells CART/CTL and DCvac Percentage of adverse effects